Intercept Pharmaceuticals (NASDAQ:ICPT) Given New $18.00 Price Target at Robert W. Baird

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) had its price objective decreased by Robert W. Baird from $35.00 to $18.00 in a research report sent to investors on Monday, The Fly reports.

A number of other analysts also recently issued reports on the company. SVB Securities lifted their price target on Intercept Pharmaceuticals from $17.00 to $18.00 in a research report on Friday, March 3rd. SVB Leerink raised their price objective on Intercept Pharmaceuticals from $17.00 to $18.00 and gave the company a market perform rating in a report on Friday, March 3rd. Needham & Company LLC raised their price objective on Intercept Pharmaceuticals from $22.00 to $26.00 and gave the company a buy rating in a report on Friday, March 3rd. Raymond James cut Intercept Pharmaceuticals from an outperform rating to a market perform rating in a report on Wednesday, May 17th. Finally, StockNews.com assumed coverage on Intercept Pharmaceuticals in a report on Thursday, May 18th. They set a hold rating on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of Hold and an average price target of $24.20.

Intercept Pharmaceuticals Stock Down 29.7 %

Shares of NASDAQ ICPT opened at $9.53 on Monday. Intercept Pharmaceuticals has a 52 week low of $9.21 and a 52 week high of $21.86. The business has a 50-day simple moving average of $15.50 and a two-hundred day simple moving average of $16.07. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 3.32. The company has a market cap of $397.28 million, a P/E ratio of 1.52 and a beta of 1.26.

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) last issued its earnings results on Thursday, March 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.11. The company had revenue of $77.22 million during the quarter, compared to the consensus estimate of $76.89 million. Research analysts anticipate that Intercept Pharmaceuticals will post -1.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Intercept Pharmaceuticals

Large investors have recently bought and sold shares of the stock. State of Wyoming purchased a new position in Intercept Pharmaceuticals in the 4th quarter worth approximately $25,000. Dark Forest Capital Management LP bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth approximately $28,000. Gladius Capital Management LP bought a new stake in shares of Intercept Pharmaceuticals in the 4th quarter worth approximately $32,000. Natixis bought a new stake in shares of Intercept Pharmaceuticals in the 4th quarter worth approximately $49,000. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Intercept Pharmaceuticals in the 3rd quarter worth approximately $58,000. 81.09% of the stock is owned by hedge funds and other institutional investors.

About Intercept Pharmaceuticals

(Get Rating)

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.